Aiforia Technologies Plc, Company release, July 31, 2026 at 6.00 p.m. EEST
Aiforia and the European Investment Bank have signed an agreement for EUR 20 million venture debt financing
Aiforia Technologies Plc ("Aiforia") and the European Investment Bank ("EIB") have today signed a binding venture debt financing agreement of up to EUR 20 million. Aiforia announced on June 15, 2026, that it had agreed with the EIB on a non-binding indicative term sheet for a venture debt financing facility of up to EUR 20 million. The main terms of the financing are in line with those previously announced. In addition, due to the venture debt nature of the financing, the terms of the financing agreement include certain non-financial covenants and other requirements that are customary for such financings, for example, related to changes of the CEO or the chairperson of the Board of Directors without EIB’s prior written consent, which reflects the confidence EIB places in Aiforia’s current management team.
The financing is divided into three tranches. The first tranche is EUR 5 million, the second EUR 7 million, and the third EUR 8 million. Drawing each tranche necessitates achieving the revenue and other interim targets defined in the financing agreement within the agreed availability periods, all of which are within 36 months of signing the binding financing agreement. Each tranche matures seven years after its respective disbursement, includes a three-year grace period, and is amortized thereafter.
In accordance with the financing agreement, Aiforia and the EIB have also agreed on a synthetic warrant arrangement, the terms of which are consistent with those announced on June 15, 2026. The synthetic warrants will be issued upon the drawdown of each loan tranche, and the arrangement does not cause immediate share dilution for Aiforia's existing shareholders.
Aiforia plans to use the financing to accelerate its product development projects related to existing and new image analysis solutions, as well as to boost its commercial operations.
“Our continent is working to remain competitive, and we need to support the companies that make that possible,” says Karl Nehammer, EIB Vice-President. “From healthcare to digital life sciences, Europe must have the best technologies developed in-house to protect and care for its citizens. The solutions developed by Aiforia strengthen Europe’s competitiveness, while giving an innovative EU company the opportunity to succeed on the global stage.”
"We are pleased that the negotiations have led to the signing of a binding financing agreement. The EIB venture debt financing strengthens Aiforia's financial position and supports the implementation of our strategy. With this financing, we can accelerate product development, expand our commercial operations internationally, and advance our goal of improving patient care through AI-powered image analysis solutions," says Jukka Tapaninen, CEO of Aiforia.
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions deployed, Aiforia is making a significant impact on pathology and healthcare. In Europe, Aiforia is the leading provider of CE-IVD marked AI-powered solutions for digital pathology.
Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France, and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.
Find out more at www.aiforia.com